Drug Profile
Research programme: RNA modulators - Ribometrix
Latest Information Update: 28 Nov 2021
Price :
$50
*
At a glance
- Originator Ribometrix
- Class Small molecules
- Mechanism of Action RNA modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Unspecified
Most Recent Events
- 28 Nov 2021 No recent reports of development identified for research development in Unspecified in USA (PO)
- 04 Oct 2019 Ribometrix and Vertex Pharmaceuticals enters collaboration agreement to discover and develop RNA targeted small molecule therapeutics
- 31 Oct 2017 Early research in Undefined indication in USA (unspecified route)